Phase 3 Study of EBI-005 in Dry Eye Disease

Summary

This is a phase III double-masked, randomized, controlled study evaluating the efficacy of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe DED three times daily for 12 weeks. Approximately 730 subjects at up to approximately 50 centers in the United States will be screened, enrolled into the study.

Timeline

Start

2014-01

Primary completion

2015-03

Completion

2015-04

Drugs

Indications